| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- наукова стаття, опублікована в травні 2011 (uk)
- مقالة علمية نشرت في 10 مايو 2011 (ar)
- scientific article published on 10 May 2011 (en)
- 2011 թվականի մայիսի 10-ին հրատարակված գիտական հոդված (hy)
- artículu científicu espublizáu en mayu de 2011 (ast)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - Tetsuya Terasaki
- Sumio Ohtsuki
- Yoshiyuki Kubo
|
| rdfs:label
| - Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. (en)
- Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. (nl)
|
| skos:prefLabel
| - Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. (en)
- Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. (nl)
|
| name
| - Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. (en)
- Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. (nl)
|
| author
| |
| author
| |
| title
| |
| title
| - Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| |
| Fatcat ID
| |
| Fatcat ID
| - release_7pujxhuukndpzg4qosaev2iqom
|
| ResearchGate publication ID
| |
| ResearchGate publication ID
| |
| is about
of | |
| is cites work
of | - Advances in the proteomic discovery of novel therapeutic targets in cancer
- Drug transport across the blood-brain barrier
- Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics
- Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro-in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques
- How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion
- Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins
- Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics.
- Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters
- Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption
- Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM.
- Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
- Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells.
- Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen.
- Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies
- Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier
- Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics
- Virtual screening of potential inhibitor against FtsZ protein from Staphylococcus aureus
- A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FV
- Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay
- Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis
- Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs.
- Quantitative targeted proteomics for membrane transporter proteins: method and application
- Advances in Proteomic Technologies and Its Contribution to the Field of Cancer
- The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development
- Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics
- Expression of periaxin (PRX) specifically in the human cerebrovascular system: PDZ domain-mediated strengthening of endothelial barrier function.
- The Promises of Quantitative Proteomics in Precision Medicine
- High performance enzyme kinetics of turnover, activation and inhibition for translational drug discovery
- Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose
- Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)